Medical Condition

peripheral t cell lymphoma

Total Trials

9

Recruiting Now

9

Trial Phases

Phase 1, Phase 2, Phase 2, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — peripheral t cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for peripheral t cell lymphoma?

ClinicalMetric currently tracks 9 actively recruiting clinical trials for peripheral t cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for peripheral t cell lymphoma?

peripheral t cell lymphoma research spans Phase 1 (5 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a peripheral t cell lymphoma clinical trial?

Eligibility criteria for peripheral t cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Institute of Hematology & Blood Diseases Hospital, China 2 trials

Peking Union Medical College Hospital 1 trial

Ruijin Hospital 1 trial

Yanyan Liu 1 trial

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 1 trial

Recruiting Clinical Trials

NCT06739265 Phase 1, Phase 2

Recruiting

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

Peking Union Medical College H...

View Trial →

NCT05675813 Phase 1, Phase 2

Recruiting

Genotype-guided Treatment in Newly Diagnosed PTCL

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Institute of Hematology & Bloo...

View Trial →

NCT06421948 Phase 1, Phase 2

Recruiting

Linperlisib Combined With Chidamide in Patients With PTCL

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Institute of Hematology & Bloo...

View Trial →

NCT07470996

Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Shanghai General Hospital, Sha...

View Trial →

NCT06508463 Phase 1

Recruiting

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT04390737 Phase 1, Phase 2

Recruiting

Evaluate the Safety and Clinical Activity of HH2853

Haihe Biopharma Co., Ltd.

View Trial →

NCT07270861

Recruiting

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Related Conditions

diffuse large b cell lymphoma (1) epigenetic repression (1) relapsed peripheral t cell lymphoma (1) peripheral t cell lymphoma not otherwise specified (1) anaplastic large cell lymphoma (1) mycosis fungoides (1) relapsed anaplastic large cell lymphoma (1) relapsed mycosis fungoides (1) fl lymphoma (1) epithelioid sarcoma (1) advanced solid tumor (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology